## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.57 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($12.98)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat**
- Source: Quiver Quantitative | 20251209T220947 | Neutral | Relevance: 100%
- Adaptive Biotechnologies will partake in a Jefferies fireside chat on December 11, 2025, to delve into Minimal Residual Disease (MRD) in Hematology/Oncology and their clonoSEQ assay technology. Dr. Harlan Robins and Susan Bobulsky will represent the company, which specializes in translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases like cancer and autoimmune disorders. This event aims to highlight their innovative diagnostics and commitment to personalized immune-driven therapies, though it lacks new specific disclosures or financial updates.

**2. Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease**
- Source: Yahoo Finance | 20251209T220947 | Somewhat-Bullish | Relevance: 98%
-  Adaptive Biotechnologies announced that Dr. Harlan Robins and Susan Bobulsky will participate in a Jefferies fireside chat on Minimal Residual Disease (MRD) in Hematology/Oncology. They will discuss the clonoSEQ assay technology on Thursday, December 11, 2025. This event highlights the company's efforts to utilize the adaptive immune system for diagnosing and treating diseases.

**3. Adaptive Biotechnologies chief commercial officer sells $212k in stock**
- Source: Investing.com | 20251209T000947 | Neutral | Relevance: 98%
-  Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, sold over $212,000 worth of company stock on December 4, 2025, while also exercising options to acquire shares. These transactions were executed under a pre-arranged trading plan, and Benzeno now directly owns 296,791 shares of the company. This comes after Adaptative Biotechnologies exceeded Q3 2025 earnings and revenue forecasts, despite a recent stock price dip.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($1.13M) |
| Sells | 11 ($5.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.2M in recent transactions.
3. Elevated short interest (8.7%): bears positioning against stock.
4. Near-term weakness: 5.6% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Insider selling cluster ($5.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.4B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -13.0% to -9.6% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 13.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.8%) - potential reversal signal. AM_20 at -7.6% indicates price below own 20MA trend. Underperforming sector by 7.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.31x) but short-term weakness (below SMA20). RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -9.58% (CS: 1) | Weak |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.924x | Below |
| vs SMA50 | 0.944x | Below |
| vs SMA200 | 1.311x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $15.42
- **Stop Loss:** $12.98 (15.8% risk)
- **Target:** $20.30 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 565
- **Position Value:** $8,712.30
- **Portfolio %:** 8.71%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*